The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors

• DOI: 10.1371/journal.pone.0132821
• Publication Date: 2015-07-15T18:21:57Z
• Authors: Agnieszka Czarniecka; Monika Kowal; Dagmara Rusinek; Jolanta Krajewska; Michal Jarzab; Ewa Stobiecka; Ewa Chmielik; Ewa Zembala-Nozynska; Stanislaw Poltorak; Aleksander Sacher; Adam Maciejewski; Jadwiga Zebracka-...; Dariusz Lange; Malgorzata Oczko-...; Daria Handkiewicz...; Barbara Jarzab
• Keywords: V600E

Introduction The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. presence BRAF mutation, the most frequent molecular event PTC, seems be a good candidate. However, there is still lack randomised trials and its significance been proved by retrospective analyses, involving large group patients. question arises whether this factor useful smaller populations, characterised specialised centres. Thus, aim study was evaluate use mutation as potential predictive marker Material 233 subjects treated between 2004-2006, were retrospectively analysed. Stage pT1 diagnosed 64.8% patients lymph node metastases 30.9%. Median follow-up 7.5 years. BRAFV600E assessed postoperatively all cases. Results V600E found 54.5%. It more > 45 years (p=0.0001), associated with larger tumour size (p=0.004). Patients tumours <= 10 mm over-represented among negative population (p=0.03). No association other clinicopathological factors observed. status neither relapse nor disease-free survival (DFS) (p=0.76). Nodal status, extrathyroidal invasion significantly influenced DFS. Conclusion recurrence mainly related invasion, whereas no impact demonstrated.